Late-onset depression and anxiety are now considered risk factors for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. It is also believed that the insidious emergence of a neurological ...
The research team of the Neurology Department Movement Disorders Unit at the Virgen del Rocío University Hospital and the Movement Disorders group of the Institute of Biomedicine of Seville - IBiS, in ...
The research team of the Neurology Department Movement Disorders Unit at the Virgen del Rocío University Hospital and the Movement Disorders group of the Institute of Biomedicine of Seville - IBiS, in ...
The significant variability of inclusion criteria presented in published studies can hinder the efforts of researchers and clinicians, according to a new report in NeuroRehabilitation Amsterdam, NL, ...
A new open-label study Sponsored by King’s College London (KCL) will assess the effects of a single psilocybin dose of 25 milligram on subjects with a diagnosis of the common and disabling Functional ...
Phase 2 ASCEND trial of solengepras, a novel, non-dopaminergic GPR6 inhibitor, showed evidence of potential benefit in ...
Daily Express US on MSN
Huntington's disease successfully decelerated by 75 percent in major breakthrough
In a world-first, scientists have unveiled a potential game-changer for Huntington's disease, sparking hope and excitement among patients and researchers alike.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback